{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:10:06Z","timestamp":1768878606944,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,9,15]],"date-time":"2006-09-15T00:00:00Z","timestamp":1158278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1186\/1471-2407-6-225","type":"journal-article","created":{"date-parts":[[2006,9,15]],"date-time":"2006-09-15T18:23:34Z","timestamp":1158344614000},"source":"Crossref","is-referenced-by-count":96,"title":["Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer"],"prefix":"10.1186","volume":"6","author":[{"given":"Laura","family":"Orlando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Ghisini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalba","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Peruzzotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Pietri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,15]]},"reference":[{"key":"577_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J: Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-364. 10.1016\/S0092-8674(00)80108-7.","journal-title":"Cell"},{"key":"577_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/319230a0","volume":"319","author":"T Yamamoto","year":"1986","unstructured":"Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB2 gene to epidermal growth factor receptor. Nature. 1986, 319: 230-234. 10.1038\/319230a0.","journal-title":"Nature"},{"key":"577_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/319226a0","volume":"319","author":"CI Bargmann","year":"1986","unstructured":"Bargmann CI, Hung MC, Wienberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986, 319: 226-230. 10.1038\/319226a0.","journal-title":"Nature"},{"key":"577_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0959-8049(97)10157-5","volume":"34","author":"F Revillion","year":"1998","unstructured":"Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998, 34: 791-808. 10.1016\/S0959-8049(97)10157-5.","journal-title":"Eur J Cancer"},{"key":"577_CR5","first-page":"43","volume":"11","author":"J Baselga","year":"1997","unstructured":"Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology. 1997, 11: 43-48.","journal-title":"Oncology"},{"key":"577_CR6","first-page":"1523","volume":"151","author":"AM Petit","year":"1997","unstructured":"Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth factor and erbB-2\/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997, 151: 1523-1530.","journal-title":"Am J Pathol"},{"key":"577_CR7","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2 (neu) signalling increases the rate of hypoxia-inducible 1 alpha (HIF-1alpha) synthesis:novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001, 21: 3995-4004. 10.1128\/MCB.21.12.3995-4004.2001.","journal-title":"Mol Cell Biol"},{"key":"577_CR8","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1091\/mbc.E02-02-0084","volume":"13","author":"L Yen","year":"2002","unstructured":"Yen L, Benlimane N, Nie ZR, Xiao D, Wang T, Al Moustafa AE, Esumi H, Milanini J, Hynes NE, Pages G, Alaoui-Jamali Ma: Differential regulation of tumor angiogenesis by distinct erbB homo and heterodimers. Mol Biol Cell. 2002, 13: 4029-4044. 10.1091\/mbc.E02-02-0084.","journal-title":"Mol Biol Cell"},{"key":"577_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/416279b","volume":"416","author":"Y Izumi","year":"2002","unstructured":"Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK: Herceptin acts as an anti-angiogenic cocktail. Nature. 2002, 416: 279-280. 10.1038\/416279b.","journal-title":"Nature"},{"key":"577_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/cncr.11656","volume":"98","author":"KS Klos","year":"2003","unstructured":"Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D: Combined trastuzumab and paclitaxel treatment better inhibits erbB2 mediated angiogenesis in breast carcinoma through a more effective inhibition of AKT than either treatment alone. Cancer. 2003, 98: 1377-1385. 10.1002\/cncr.11656.","journal-title":"Cancer"},{"key":"577_CR11","first-page":"1673","volume":"23","author":"MI Koukurakis","year":"2003","unstructured":"Koukurakis MI, Simopoulos C, Polychronidis A, Perente S, Botaitis S, Giatromanolaki A, Sivridis E: The effect of trastuzumab\/docetaxel combination on breast cancer angiogenesis:dichotomus effect predictable by the HIFIa\/VEGF pre-treatment status?. Anticancer Res. 2003, 23: 1673-1680.","journal-title":"Anticancer Res"},{"key":"577_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/annonc\/mdf013","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nol\u00e8 F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002, 13: 73-80. 10.1093\/annonc\/mdf013.","journal-title":"Ann Oncol"},{"issue":"2","key":"577_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/annonc\/mdj066","volume":"17","author":"M Colleoni","year":"2006","unstructured":"Colleoni M, Orlando L, Sanna G, Rocca A, Maissonneuve A, Sandri MTP, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nol\u00e8 F, Viale G, Goldhirsch A: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Annals Oncol. 2006, 17 (2): 232-8. 10.1093\/annonc\/mdj066.","journal-title":"Annals Oncol"},{"key":"577_CR14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0959-8049(00)00092-7","volume":"36","author":"RS Kerbel","year":"2000","unstructured":"Kerbel RS, Viloria-Petit A, Klement G, Rak J: \"Accidental\" antianiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotharapeutic agents as examples. Eur J Cancer. 2000, 36: 1248-1257. 10.1016\/S0959-8049(00)00092-7.","journal-title":"Eur J Cancer"},{"key":"577_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"key":"577_CR16","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","volume":"19","author":"HJ Burstein","year":"2001","unstructured":"Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP: Clinical activity of trastuzumab and vinorelbine in women with HER2 overexpressing metastatic breast cancer. J Clin Oncol. 2001, 19: 2722-2730.","journal-title":"J Clin Oncol"},{"key":"577_CR17","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1200\/JCO.2002.07.058","volume":"20","author":"FJ Esteva","year":"2002","unstructured":"Esteva FJ, Valero V, Bosser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN: Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20: 1800-1808. 10.1200\/JCO.2002.07.058.","journal-title":"J Clin Oncol"},{"key":"577_CR18","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","volume":"16","author":"MD Pegram","year":"1998","unstructured":"Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 monoclonal antibody plus cisplatin in patients with HER2\/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998, 16: 2659-2671.","journal-title":"J Clin Oncol"},{"issue":"3","key":"577_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/1078-0432.CCR-05-1109","volume":"12","author":"JM du Manoir","year":"2006","unstructured":"du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Vigoria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS: Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006, 12 (3): 904-916. 10.1158\/1078-0432.CCR-05-1109.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"577_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3816\/CBC.2005.n.035","volume":"6","author":"JA Garcia-Saenz","year":"2005","unstructured":"Garcia-Saenz JA, Martin M, Puente J, Lopez-Tarruella S, Casado A, Moreno F, Grande E, Diaz-Rubio E: Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast cancer. 2005, 6 (4): 325-329.","journal-title":"Clin Breast cancer"},{"key":"577_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3816\/CBC.2004.n.010","volume":"5","author":"KA Gelmon","year":"2004","unstructured":"Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R: Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004, 5: 52-58.","journal-title":"Clin Breast Cancer"},{"key":"577_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3816\/CBC.2003.n.017","volume":"4","author":"G Fountzilas","year":"2003","unstructured":"Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer. 2003, 4: 120-125.","journal-title":"Clin Breast Cancer"},{"key":"577_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of Her2\/neu oncogene. Science. 1987, 235: 177-182.","journal-title":"Science"},{"issue":"4","key":"577_CR24","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W","volume":"58","author":"D Rosner","year":"1986","unstructured":"Rosner D, Nemoto T, Lane WW: Chemotherapy induces regression of brain metastasis in breast carcinoma. Cancer. 1986, 58 (4): 832-9. 10.1002\/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W.","journal-title":"Cancer"},{"key":"577_CR25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","volume":"22","author":"D Tripathy","year":"2004","unstructured":"Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004, 22: 1063-1070. 10.1200\/JCO.2004.06.557.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-6-225\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T22:27:05Z","timestamp":1548109625000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-6-225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,15]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-6-225","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,15]]},"article-number":"225"}}